Pfizer 2011 Annual Review | Pfizer: the world's largest research-based pharmaceutical company READ

At Our Core:

Innovation. Humanity.

Leading in the business of innovative life science, we remain focused on what matters: the health needs of people and how best to meet them.

We are dedicated, as people and as a business, to leading the research-based biopharmaceutical industry in productive, responsible and beneficial life science.

Our Imperatives

As a leader in this vital industry, our purpose is clear: applying innovative science to improve health and well-being. The actions we take are crucial, not only to our success as a business, but also to the lives of those who count on us to succeed.

Read more

Our Imperatives

As a leader among biopharmaceutical businesses, our purpose is clearly stated: apply innovative science to improve health and well-being. Success here is crucial, first and foremost to patients awaiting new treatments, but also to those who invest in us and work with us.

We are focusing on four overarching priorities—we call them "imperatives"—to enable us to position Pfizer for success and differentiate the company from our competitors.

We focus collaborative, breakthrough science on addressing unmet needs with medicines and vaccines that profoundly affect health and well-being.

Precision Medicine —
The Xalkori Story

The leading edge of innovation in biopharmaceuticals may be precision medicines—therapies focused sharply on a disease caused by a very specific gene deficiency or mutation. Xalkori, for certain types of lung cancer, vaulted Pfizer into prominence in precision medicine in 2011.

Read more

Precision Medicine — The Xalkori Story

Research-based pharmaceutical companies are facing key challenges today due to increasing costs, long cycle times, high late-stage attrition, and technological and genomic breakthroughs that have increased R&D complexity. In 2011, we made significant changes in our R&D model to facilitate the flow of important medicines and vaccines. We launched a three-phase, multiyear effort to accelerate Pfizer's R&D strategy and create an engine for sustainable innovation (ESI).

2011 stands as a banner year for our reinvigorated pipeline. A number of new medicines and indications were approved, underscoring our ability to channel science to patient benefit. And as the recently fast-tracked and approved Xalkori (crizotinib) in the U.S. attests, our commitment to Precision Medicine holds promise for patients and our business.

A new, more expansive approach to external collaboration is essential to our R&D strategy. Our Centers for Therapeutic Innovation embed small groups of Pfizer scientists within leading academic medical centers, in the interest of shaping the future and speeding our progress.

We embrace the business of innovative life science because of what it can do, and what we are doing, to improve lives all around the world.

Life Lessons

Life is teaching us many things, encouraging us to embrace health and well-being at every stage of life, and to foster a new age of aging well.

Read more

Life Lessons

Our efforts to help humanity must also make business sense. And they do. Improving health and well-being is our business. Working to raise standards of health care, improve access and help support economic development around the world creates more demand for what we offer and helps to open new markets—and new opportunities in established ones. Finding, creating and adapting business models that can work in developing and underserved markets hones our skills, expands our impact and grows our business, while bringing essential health care and services to people in need.

Patient safety is absolutely integral to our success and to how we organize all our business processes. We work to ensure safety in everything we do with patients, from initial human trials to post-marketing studies, and encompassing the complete life cycle of our medicines from initial development through off-patent and generic phases. We take a long view of productivity, taking into account environmental effects, and we are working hard to reduce our environmental footprint even as we grow and reach millions of new people.

This is all in support of building a sustainable global enterprise that meets the needs of all our stakeholders, year after year.